The increase was primarily driven by an upfront payment and funding associated with the Vivet gene therapy programs and costs associated with the ...
https://www.google.com/url?rct=j&sa=t&url=https://www.businesswire.com/news/home/20210805005953/en/Mirum-Pharmaceuticals-Reports-Second-Quarter-2021-Financial-Results-and-Provides-Business-Update&ct=ga&cd=CAIyGmEyNDJjNTAxZWU3OTQyNzI6Y29tOmVuOlVT&usg=AFQjCNGg1UjRBSiNqh4TdRxqSDv-75Uu0g
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.